Prevention of prostate cancer by natural product MDM2 inhibitor GS25: in vitro and in vivo activities and molecular mechanisms

Wang, Wei; Qin, Jiang‐Jiang; Li, Xin; Tao, Gabriel; Wang, Qiang; Wu, Xuming; Zhou, Jianwei; Zi, Xiaolin; Zhang, Ruiwen

doi:10.1093/carcin/bgy063

Cited by 26 publications

(20 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other types of MDM2 inhibitors, especially those that directly inhibit MDM2 itself, for example, SP141, JapA, and MA242, should be evaluated for their therapeutic efficacy and safety, as they may provide stronger activity by blocking both the p53‐dependent and p53‐independent functions of MDM2. Further evaluation and development of MDM2 inhibitors for cancer therapy are underway . These studies will provide proof‐of‐principle results to support the therapeutic value of this targeting strategy in drug discovery and may greatly contribute to the development of new therapeutics to treat noncancer diseases.…”

Section: General Discussion and Future Research Directionsmentioning

confidence: 90%

Targeting MDM2 for novel molecular therapy: Beyond oncology

Wang

Qin

Rajaei

et al. 2019

Medicinal Research Reviews

Self Cite

View full text Add to dashboard Cite

The murine double minute 2 (MDM2) oncogene exerts major oncogenic activities in human cancers; it is not only the bestdocumented negative regulator of the p53 tumor suppressor, but also exerts p53-independent activities. There is an increasing interest in developing MDM2-based targeted therapies. Several classes of MDM2 inhibitors have been evaluated in preclinical models, with a few entering clinical trials, mainly for cancer therapy. However, noncarcinogenic roles for MDM2 have also been identified, demonstrating that MDM2 is involved in many chronic diseases and conditions such as inflammation and autoimmune diseases,

show abstract

Section: General Discussion and Future Research Directionsmentioning

confidence: 90%

Targeting MDM2 for novel molecular therapy: Beyond oncology

Wang

Qin

Rajaei

et al. 2019

Medicinal Research Reviews

Self Cite

View full text Add to dashboard Cite

show abstract

“…The MDM2/MDMX-p53 circuitry plays a pivotal role in cancer cell proliferation, cell cycle progression, apoptosis, and senescence (Karni-Schmidt et al, 2016;Wang et al, 2019b), while USP7 is a critical regulator of this circuitry and tightly controls the stabilities of these proteins, thereby contributing to cancer initiation, progression, and metastasis (Bhattacharya et al, 2018;Rawat et al, 2019). Many MDM2/MDMX inhibitors have been developed for cancer therapy Wang et al, 2018aWang et al, ,b, 2019bde Oliveira Ribeiro et al, 2020), and some of them are in clinical trials (Liu et al, 2019b;Rafal et al, 2019). Most of the MDM2/MDMX inhibitors are designed to target the MDM2/p53 and MDMX/p53 interactions, and wildtype p53 is critical for their anticancer activity (Liu et al, 2019b;Rafal et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

“…In colorectal cancer cells, USP7 may regulate the deubiquitination of β-catenin, although the detailed binding mechanisms need to be further investigated . Considering that MDM2 and MDMX are highly expressed in prostate, breast, cervical, and colorectal cancer (Cressey et al, 2006;Voruganti et al, 2015;Qin et al, 2016aQin et al, ,b, 2017Stiasny et al, 2017;Wang et al, 2018a), USP7-mediated stabilization of MDM2 and MDMX may also contribute to the progression of these diseases.…”

Section: The Role Of Usp7-mdm2/mdmx-p53 Network In Human Cancer and Imentioning

confidence: 99%

Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?

Cheng

et al. 2020

Front. Cell Dev. Biol.

Self Cite

View full text Add to dashboard Cite

The p53 tumor suppressor protein and its major negative regulators MDM2 and MDMX oncoproteins form the MDM2/MDMX-p53 circuitry, which plays critical roles in regulating cancer cell growth, proliferation, cell cycle progression, apoptosis, senescence, angiogenesis, and immune response. Recent studies have shown that the stabilities of p53, MDM2, and MDMX are tightly controlled by the ubiquitinproteasome system. Ubiquitin specific protease 7 (USP7), one of the most studied deubiquitinating enzymes plays a crucial role in protecting MDM2 and MDMX from ubiquitination-mediated proteasomal degradation. USP7 is overexpressed in human cancers and contributes to cancer initiation and progression. USP7 inhibition promotes the degradation of MDM2 and MDMX, activates the p53 signaling, and causes cell cycle arrest and apoptosis, making USP7 a potential target for cancer therapy. Several small-molecule inhibitors of USP7 have been developed and shown promising efficacy in preclinical settings. In the present review, we focus on recent advances in the understanding of the USP7-MDM2/MDMX-p53 network in human cancers as well as the discovery and development of USP7 inhibitors for cancer therapy.

show abstract

“…Prevention is still an important strategy to reduce adverse effects and mortality of prostate cancer ( 27 ). According to Wang et al, new approaches should be developed to prevent primary and metastatic prostate cancer ( 28 ). In our proposed model, preventive care of prostate cancer through the mobile application is provided as a new supportive approach.…”

Section: Discussionmentioning

confidence: 99%

A Contribution into Developing a Model for Prostate Cancer Self-Care Mobile Application

2018

View full text Add to dashboard Cite

Introduction:New Healthcare models are developed with the focus on the community members and towards their self-accomplishment of the healthy activities. Mobile Health, as a newbie technology, seems to be appropriate to help prostate cancer self-care.Aim:this study aimed to provide a comparative model of mobile application for prostate cancer care self-care for Iranians.Material and Methods:This is an applied mixed method study, which was conducted in three phases from 2017 to 2018 as follows: 1) searching and thematic content analyzing of prostate cancer mobile applications and their related articles to extract technical features and clinical functions; 2) selecting the common extracted features and functions to design an initial model of the application; and 3) confirming validity of the features and functions through 2 rounds of Delphi technique.Results:This applied model was developed for the appropriate prostate cancer self-care, with such functionalities as user training, care, diagnosis, interaction, and alerting the user. Also, some technical features of the model include settings and data sharing.Conclusion:The applied model of mobile application for prostate cancer has been done in compliance with requirements of Iranian health information technologists, urologists and oncologists. It seems it would be of help in self-care of patients with needed to prostate cancer care.

show abstract

Prevention of prostate cancer by natural product MDM2 inhibitor GS25: in vitro and in vivo activities and molecular mechanisms

Cited by 26 publications

References 40 publications

Targeting MDM2 for novel molecular therapy: Beyond oncology

Targeting MDM2 for novel molecular therapy: Beyond oncology

Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?

A Contribution into Developing a Model for Prostate Cancer Self-Care Mobile Application

Contact Info

Product

Resources

About